Cardio Diagnostics (NASDAQ:CDIO) Issues Quarterly Earnings Results

Posted by Stanley Muller on Nov 6th, 2026

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) released its earnings results on Friday. The company reported ($0.59) EPS for the quarter, Zacks reports. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative return on equity of 82.28%.

Cardio Diagnostics Stock Performance

Shares of CDIO remained flat at $1.68 during midday trading on Friday. The company’s stock had a trading volume of 18,908 shares, compared to its average volume of 23,643. The company’s fifty day moving average is $1.84 and its 200-day moving average is $2.06. The stock has a market capitalization of $4.96 million, a P/E ratio of -0.57 and a beta of 2.32. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $7.91.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. According to MarketBeat, Cardio Diagnostics has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on CDIO

Cardio Diagnostics Company Profile

(Get Free Report)

Cardio Diagnostics Holdings, Inc is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care.

The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.